Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06428019
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-05-20
Brief Title:
A Study to Evaluate the Risk of Tumor Lysis Syndrome TLS in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia CLL
Sponsor:
AbbVie
Organization:
AbbVie
Organization Data
Organization:
AbbVie
Class:
INDUSTRY
Study ID:
M24-287
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
AbbVie
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None